Please assess the completion status of the following clinical trial:

Trial Title: Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females aged 6 to 12 years at the time of screening, inclusive~2. Diagnosed with ADHD by a psychiatrist within 6 months of study enrolment or newly diagnosed with ADHD using the DSM-5 criteria for ADHD~3. An ADHD-RS-5 score at Screening ≥90th percentile for sex and age in at least one of the following categories:~   1. Hyperactive-impulsive subscale,~  2. Inattentive subscale, or~  3. Total score. Subjects who do not meet this criteria at screening can have ADHD-RS-5 repeated at baseline, after washout of stimulant medication for a minimum of 24 hours prior to baseline.~4. In the clinical judgment of the Investigator, the subject must be in need of pharmacological treatment for ADHD.~5. Females of childbearing potential must be non-lactating and must have a negative serum pregnancy test at screening~6. Provide written informed consent (parent/guardian) and assent (child aged 10 - 12 years only) prior to participation in the study~Exclusion Criteria:~1. Diagnosed with any DSM-5 active disorder (other than ADHD) with the exception of specific phobias, learning disorders, motor skills disorders, communication disorders, oppositional defiant disorder, elimination disorders, and sleep disorders~2. Known history of chronic medical illnesses including severe hypertension, untreated thyroid disease, peripheral vasculopathy, known structural cardiac disorders, serious cardiac conditions, serious arrhythmias, cardiomyopathy, known family history of sudden death~3. Known history or presence of significant renal or hepatic disease, as indicated by clinical laboratory assessment (liver function test results ≥ two times the upper limit of normal, blood urea nitrogen, or creatinine).~4. Clinically significant abnormal ECG or cardiac findings on physical examination (including the presence of a pathologic murmur)~5. Use of the following medications within 30 days of Baseline Visit:~   * MAOI - monoamine oxidase inhibitors (e.g., Selegiline, isocarboxazid, phenelzine, tranylcypromine)~  * Tricyclic Antidepressants (e.g. Desipramine, protriptyline)~6. Use of the following medications within 3 days of Baseline Visit~   * Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid HCl, ascorbic acid)~  * Urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate, methenamine salts)~7. Use of atomoxetine within 14 days of Baseline Visit~8. Planned use of prohibited drugs or agents from the Screening visit through the end of the study~9. Abnormal clinically significantly laboratory test value at screening that, in the opinion of the Investigator, would preclude study participation~10. Known history of allergy/hypersensitivity to amphetamine or any of the components of Dyanavel XR, or topical anaesthetics~11. Known history of lack of response to amphetamine~12. Parent or guardian's inability or unwillingness to follow directions of the Investigator or study research staff.~13. Any uncontrolled medical condition that in the opinion of the Investigator would preclude study participation~14. History of significant illness requiring hospitalization, or surgery requiring anaesthetics within 30 days of Baseline Visit

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Active Treatment (Type: ACTIVE_COMPARATOR): Double blind amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM
- Placebo Treatment (Type: PLACEBO_COMPARATOR): Double blind placebo, 6, 7 or 8 mL po QAM

Based on this trial design, predict the completion outcome and termination type (if applicable).